Compare Shell PLC (SHEL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Shell PLC trades at $100.36 (market cap $284.34B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Shell PLC is far larger — about 28.1× State Street SPDR S&P Biotech ETF's market cap, and Shell PLC pays a 3.12% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Shell PLC for 90 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SHEL | XBI | |
|---|---|---|
Market Cap | $284.34B | $10.11B |
Volume | 9,097,469 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $100.20 | $169.55 |
52-Week Low | $70.31 | $104.99 |
Typical Hold Time | 90 Days | 38 Days |
Enterprise Value | $326.04B | — |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $100.18, up 3.44% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with a P/E of 11.08, ROE of 14.35%, and recent earnings beats. Recent developments include the LNG Canada Phase 2 expansion approval, doubling export capacity, positioning Shell for long-term LNG growth. Cash flow remains healthy despite a temporary net outflow in 2025.
Shell presents a compelling investment case with attractive valuation, strong profitability, and strategic LNG expansion. Risks include revenue volatility from oil prices and execution challenges in major projects. Analyst consensus is bullish with a $102.53 price target, suggesting modest upside from current levels.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
